Formulation and Drug Delivery

Novavax and Par Sterile Products Enter into Fill/Finish Manufacturing and Services Agreement for COVID-19 Vaccine Candidate

September 28, 2020

Par Sterile will produce the vaccine for use in Novavax's Phase III clinical trial in the United States, while also providing fill/finish services for commercial distribution in the US.

GRAM Partners with Johnson & Johnson for Fill/Finish of Vaccine Candidate

September 28, 2020

GRAM is expanding fill/finish capacity and is working with Janssen on tech transfer in preparation for production of Janssen’s SARS-CoV-2 vaccine candidate at GRAM’s Grand Rapids, MI facility.

Novavax Begins Phase III Efficacy Trial of COVID-19 Vaccine

September 25, 2020

A clinical trial to enroll up to 10,000 volunteers across the UK will assess whether NVX-CoV2373 is effective in the prevention of COVID-19.

UK Prime Minister Visits Team Behind the Vaccines Manufacturing and Innovation Centre

September 24, 2020

UK's Prime Minister visited the site of the country’s VMIC in Oxfordshire, and met the teams working at the forefront of the national COVID-19 response.

Johnson & Johnson Launches Multi-Country Phase III Trial of Janssen’s COVID-19 Vaccine Candidate

September 23, 2020

A Phase III trial to evaluate safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S, is enrolling participants on three continents.

Stevanato Group Partners with Bexson Biomedical on a Wearable Drug Delivery Device

September 22, 2020

The companies will work together to produce a wearable device that can subcutaneously deliver ketamine therapy as a non-opioid pain treatment.

Sanofi and GSK to Provide the EU with 300 Million Doses of its COVID-19 Vaccine Candidate

September 21, 2020

The companies will receive upfront funding from the European Union for the scale-up of manufacturing capabilities at industrial sites in Belgium, Italy, Germany, and France.

Lonza, Humanigen Partner to Expand Manufacturing of Lenzilumab for Potential COVID-19 Therapy

September 18, 2020

The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.

Novavax in COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India

September 18, 2020

The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.

Lilly and Amgen in Manufacturing Collaboration for COVID-19 Antibody Therapies

September 18, 2020

The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.